Noile-Immune Biotech announces agreement on the license of NIB-102 and NIB-103 with Takeda


Tokyo, Japan, January 3, 2019

 

Noile-Immune Biotech Inc. announced that Noile made exclusively license to Takeda NIB-102 and NIB-103 for the treatment of various solid tumor indications, and will co-develop these CAR-T cell therapies with Takeda utilizing the Noile’s proprietary “Prime” (proliferation inducing and migration enhancing) CAR-T technology, generated by Koji Tamada, M.D., Ph.D., Scientific Founder of Noile. The company plans to gain regulatory approval for human testing of NIB-102 by the end of this year..

This agreement is due to the success of the research collaboration, which originated in September 2017, and Takeda not only exercised an option under the collaboration, but also licensed new pipeline.

We are very pleased to step into a next stage of alliance with Takeda to promote cell therapy strategically. This agreement is the first milestone of our Prime technology with a third-party evaluation of pharmaceutical company. We believe that this will be the chance to apply our technology broadly across the cell therapy products and companies in future. In order to deliver the best-in-class therapy for cancer patients, our company will promote our research and development, and also partnership with more pharmaceutical companies.” said Hidenobu Ishizaki, M.D., Ph.D., President and CEO of Noile.

Under the terms of the agreement, Noile will receive an option excise payment, upfront payment and development milestones. Noile will also receive royalties based on sales of the licensed NIB-102 and NIB-103. Additional terms of this agreement are not disclosed.

Takeda signed an agreement with Noile through its wholly-owned subsidiary, Millennium Pharmaceuticals, Inc.